<div id="readability-page-1"><div><ul> <li>In recent days, Ryan Specialty Holdings reported weaker-than-expected fourth-quarter and full-year 2025 results, while also facing securities law investigations and hosting its investor presentation at the Morgan Stanley US Financials Conference 2026 in New York.</li> <li>At the same time, a mix of analyst downgrades, securities law scrutiny, and increased insider share purchases has put a spotlight on how confident management really is in the company’s long-term prospects.</li> <li>We’ll now examine how softer organic growth and margin pressure may influence Ryan Specialty’s previously optimistic investment narrative.</li> </ul><p>The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.</p><h2>Ryan Specialty Holdings Investment Narrative Recap</h2><p>To own Ryan Specialty, you need to believe its wholesale and specialty focus can withstand softer organic growth, margin pressure, and a choppier property cycle. Right now, the key short term catalyst is how quickly growth and margins can stabilize after the weaker 2025 results, while the biggest risk is that prolonged pricing softness and securities law scrutiny keep weighing on sentiment. The latest news does not remove these risks, but it sharpens investor attention on them.</p> <p>The expanded US$300.0 million share repurchase authorization stands out in this context. It sits alongside recent insider buying and offers a contrasting signal to the analyst downgrades tied to weaker organic growth and softer guidance for 2026. For investors, the buyback program and insider purchases highlight how capital allocation decisions intersect with the very same pricing and margin concerns now under review by both analysts and securities law firms.</p> <p>Yet beneath the buybacks and insider buying, there is a separate risk investors should be aware of around potential securities law findings and what they could mean for...</p> <p>Read the full narrative on Ryan Specialty Holdings (it's free!)</p><p>Ryan Specialty Holdings' narrative projects $4.5 billion revenue and $1.1 billion earnings by 2028. This requires 17.6% yearly revenue growth and an earnings increase of about $1.0 billion from $57.8 million today.</p><p>Uncover how Ryan Specialty Holdings' forecasts yield a $55.25 fair value, a 55% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3f9965-caa3-43f6-969d-a403a34bcb59/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3f9965-caa3-43f6-969d-a403a34bcb59/chart/quote-price"/><figcaption>RYAN 1-Year Stock Price Chart</figcaption></figure> <p>The most pessimistic analysts were already assuming about US$4.1 billion of revenue and US$542.6 million of earnings by 2029, yet after this setback you can see how views on automation risk and earnings stability might diverge even further.</p><p>Explore 4 other fair value estimates on Ryan Specialty Holdings - why the stock might be worth as much as 55% more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Ryan Specialty Holdings research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Ryan Specialty Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ryan Specialty Holdings' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.</li><li>AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

RYAN

<p>Ryan Specialty Holdings reported weaker-than-expected Q4 and full-year 2025 results, facing securities law investigations and analyst downgrades. Despite margin pressure and softer organic growth, the company announced a $300 million share repurchase authorization and saw increased insider buying, signaling management confidence. The firm projects $4.5 billion revenue by 2028, with analysts debating the sustainability of its growth narrative amid pricing softness and regulatory scrutiny.</p>

Simplywall

Ryan Specialty

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Ryan Specialty (RYAN) Faces Weaker Results and Scrutiny Is Management’s Confidence Still Convincing?